A healthcare worker prepares a flu vaccine before administering it to a community population on December 17, 2022 in Los Angeles, USA.
Xinhua News Agency | Getty Images
Ann advisory board to the Centers for Disease Control and Prevention on Wednesday Recommended Adults over the age of 60 should consult a physician before taking one dose. RS virus vaccine from Pfizer and GSKMore.
Commission said older people should use “Sharing Clinical Decisions” This includes working with health care providers to determine how much benefit can be gained from vaccination.
CDC Director Resigns Rochelle Wallensky Decide whether to finalize recommendations.
Panel decision takes US one step closer to attack respiratory syncytial virus It generally opens to the public this fall, which is usually when the disease starts to spread at higher levels.
This recommendation is also coming out weeks after the Food and Drug Administration. both approved vaccine and will be the world’s first licensed vaccine against RSV.
The virus is a common respiratory infection that usually causes mild cold-like symptoms but more severe symptoms in the elderly and children. Every year, RSV kill According to the CDC, there are 6,000 to 10,000 seniors and hundreds of children under the age of five.
Pfizer and GSK both submitted new clinical trial data to the committee on Wednesday, providing the first glimpse into the RSV’s shot durability after one season. In the northern hemisphere this season usually lasts from he October to he March.
A single dose of Pfizer’s vaccine 78.6% effective It is effective in preventing lower respiratory tract disease with three or more symptoms through the middle of the second RSV season, according to new clinical trial results released Wednesday. This is down from over 85% at the end of the seniors first season.
Pfizer said its efficacy for mild disease in the same age group dropped from about 66% to 48.9% “midway through Season 2.”
GSK had one shot. 78.8% effective The company said Wednesday that its infection rate for severe respiratory syncytial virus infection was 94% after two seasons, and 94% after one season. A serious illness is one that interferes with normal daily activities.
For less severe RSV disease, efficacy declined from 82% after one season to 67.2% after two seasons.
CDC medical officer Dr. Michael Melger, who evaluated the data from both vaccinations, said at a public meeting that both Pfizer and GSK still lack efficacy data on the subgroups of the elderly population most at risk for severe RSV. pointed out that
Melgar said the companies’ Phase III clinical trials underrepresented adults over the age of 75 and those with underlying medical conditions. Elderly people with weakened immune systems were completely excluded from the trial, he said.
The companies said studies on these populations are ongoing.
It is not yet known how much the filming will cost. GSK is pricing the vaccine between $200 and $295. Pfizer said the shot will cost between $180 and $270.
Both companies declined to vouch for the price.
This shot will help the US compete against the RSV season, which starts in the fall. unusually serious Last year’s RSV season.
Virus-infected children and the elderly flooded hospitals across the country. This is mainly because the public has stopped medical practice. COVID Pandemic health measures that helped limit the spread of RSV.
